Pharmafit Provence
GRANIONS DE MANGANESE 0,1 mg/2 ml S buv en ampoule 30Amp/2ml

GRANIONS DE MANGANESE 0,1 mg/2 ml S buv en ampoule 30Amp/2ml

VIDAL information
Your professional account

PharmaFit supplies pharmacies and healthcare professionals. Access your purchasing terms and availability through your professional account.

Access is reserved for authorised professionals, following account approval.

Contact PharmaFit

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
SmPC of 19/09/2023

MANGANESE GRANIONS 0,1 mg/2 mL, oral solution in ampoule


Forms and presentations

Oral solution.
Ampoule with two self-breaking tips of 2 mL. Box of 30.


Composition

For one ampoule of 2 ml:

Manganese sulfate monohydrate: 0,306 mg
Quantity corresponding to elemental manganese: 0,100 mg


Excipients:

Amylose, glycerol, purified water.



Indications

Used as a terrain modifier, in particular during allergic conditions.



Dosage and administration

Dosage

RESERVED FOR ADULTS.

Oral use.

1 to 2 ampoules per day

Method of administration

To be diluted in a glass of water, outside meals.



Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section Composition.



Warnings and precautions

Treatment with this trace mineral element does not replace any specific treatment that may be needed.



Interactions

The data available to date do not suggest the existence of clinically significant interactions.



Fertility, pregnancy and breastfeeding

In the absence of experimental and clinical data, and as a precaution, use of this medicine should be avoided during pregnancy and breastfeeding.



Driving and using machines

MANGANESE GRANIONS 0,1 mg/2 mL, oral solution in ampoule has no effect on the ability to drive vehicles or use machines.



Adverse effects

No adverse effect has been reported with the use of MANGANESE GRANIONS 0,1 mg/2 mL, oral solution in ampoule.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/.



Overdose

No cases of overdose have been reported with this specialty.

With chronic administration at high doses, neurological symptoms have been observed with manganese



Pharmacodynamics

Pharmacotherapeutic class: OLIGOTHERAPY (V: Miscellaneous)

Trace mineral element.



Preclinical safety

Preclinical safety data in animals are insufficient to assess the toxicity of manganese sulfate monohydrate with respect to reproductive functions.



Shelf life

2 years.



Special storage precautions

No special precautions for storage.



SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

No special requirements.



Prescription, supply and reimbursement

Marketing authorisation (AMM)
CIP 3400937545969 (30Amp/2ml).
Not reimbursed by Social Security.

GRANIONS EA-PHARMA Laboratory
Le Parador II
5, allée Crovetto-Frères. 98000 Monaco
Tel: 00 377 92 05 76 30

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.